Norditropin Flexpro (Somatropin)

Somatropin binds to growth hormone receptors on cell surfaces, activating the JAK2‑STAT5 pathway. This triggers the liver to produce insulin‑like growth factor‑1 (IGF‑1), which mediates most of the anabolic and growth‑promoting effects, including increased protein synthesis, bone growth, and lipolysis, while also influencing carbohydrate metabolism.

The dose of Norditropin Flexpro is individualized. A qualified prescriber determines the appropriate amount based on the patient’s age, weight, clinical condition, and IGF‑1 response. Dosing is typically adjusted periodically to achieve target growth parameters while minimizing adverse effects.

Safety of somatropin in pregnancy or while breastfeeding has not been established. It should only be used if the potential benefit justifies the potential risk to the fetus or infant. Women who are pregnant, planning pregnancy, or nursing should discuss alternatives with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and necessary import documentation.

Norditropin Flexpro is a recombinant somatropin formulation delivered via a flexible pen device, offering precise dosing and ease of subcutaneous administration. Compared with other brands, it provides comparable efficacy and safety profiles, while the pen system may improve patient adherence and reduce injection‑site discomfort.

Norditropin Flexpro should be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking. If a short period outside the refrigerator is unavoidable, it may remain at room temperature for up to 28 days, as specified in the product labeling.

The medication is administered subcutaneously using the supplied pen device. The injection site is typically rotated among the abdomen, thigh, or upper arm. Patients or caregivers should follow the prescriber’s instructions for dose preparation, injection technique, and disposal of used needles.

Serious risks include intracranial hypertension, slipped capital femoral epiphysis, worsening of glucose tolerance or diabetes, and the potential acceleration of pre‑existing malignancies. Patients should be monitored regularly for signs of these conditions, and therapy should be discontinued if severe adverse events occur.

Norditropin Flexpro is contraindicated in individuals with active malignancy, hypersensitivity to somatropin or any excipients, and those with uncontrolled diabetes or severe edema. Caution is also advised for patients with chronic renal failure, active infection, or a history of intracranial hypertension.